Drug Approval | July 14, 2023
Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
This product will be launched through Granules Consumer Health (GCH) division
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Approval to dramatically change CAR-T therapies landscape
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Subscribe To Our Newsletter & Stay Updated
